Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GLK-221 in Keratoconus
NCT07400952Phase 2Recruiting
- Sponsor
- Glaukos Corporation
- Start
- Dec 2025
- Primary completion
- Apr 2027
- Countries
- 1
01
Overview
A Phase 2 trial of GLK-221 in keratoconus, sponsored by Glaukos Corporation. Started Dec 2025; status: recruiting.
02
Drugs
GLK-221
03
Conditions
keratoconus
Beyond the preview
Go deeper on NCT07400952.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07400952.